---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-094391"
form_type: "8-K"
ticker: "TECH"
cik: "0000842023"
company_name: "BIO-TECHNE Corp"
filed_at: "2026-08-12T10:30:30+00:00"
generated_at: "2026-08-12T10:35:10.188782+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bio-Techne Q4 revenue $321M, adjusted EPS $0.52; dividend $0.08; Merck deal on track

## Summary
- Q4 revenue $321.2M (+1% reported, +3% organic); FY26 flat at $1.2B
- Q4 GAAP EPS $0.35 vs $(0.11) prior year; adjusted EPS $0.52 vs $0.53
- FY26 GAAP EPS $1.16 vs $0.46; adjusted EPS $1.93 vs $1.92
- Quarterly dividend $0.08/share, payable Sept 4, 2026, record Aug 24
- Merck KGaA acquisition at $73/share cash, ~$11.3B EV, on track

## SEC filing metadata
- accession: 0001104659-26-094391
- form_type: 8-K
- ticker: TECH
- cik: 0000842023
- company_name: BIO-TECHNE Corp
- filed_at: 2026-08-12T10:30:30+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/842023/000110465926094391/0001104659-26-094391-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/842023/000110465926094391/tech-20260812x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-094391
- JSON: https://secwatch.observer/filing/0001104659-26-094391.json
- Plain text: https://secwatch.observer/filing/0001104659-26-094391.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.